Cargando…

Methodological quality of studies of end-stage renal disease risks in lupus nephritis

Detalles Bibliográficos
Autores principales:	Tektonidou, Maria, Dasgupta, Abhijit, Ward, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179579/ http://dx.doi.org/10.1186/ar4663

Ejemplares similares

Contemporary estimates of the risk of end-stage renal disease in the first decade of proliferative lupus nephritis
por: Ward, MM, et al.
Publicado: (2012)

Variation in renal biopsy and medication prescribing practices among pediatric Medicaid patients with lupus nephritis prior to end-stage renal disease in the US, 2000 to 2004
por: Hiraki, LT, et al.
Publicado: (2012)

Molecular characterization of proliferative lupus nephritis
por: Parikh, Samir V, et al.
Publicado: (2014)

Differing environmental risk factors for membranous versus proliferative lupus nephritis
por: Dooley, MA, et al.
Publicado: (2012)

Usual source of care and geographic region are largest predictors of healthcare quality for incident lupus nephritis in US Medicaid recipients
por: Yazdany, J, et al.
Publicado: (2012)

Time to lupus nephritis: impact of gender and ethnicity
por: Seligman, VA, et al.
Publicado: (2001)

Cytokine profiles of lupus patients with or without nephritis
por: Rovin, BH, et al.
Publicado: (2012)

Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis
por: Parikh, S, et al.
Publicado: (2012)

Identification of stage-specific genes associated with lupus nephritis and response to remission induction in NZB/W and NZM2410 mice
por: Bethunaickan, Ramalingam, et al.
Publicado: (2014)

Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006
por: Feldman, Candace H, et al.
Publicado: (2014)

Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis
por: Clark, Marcus R, et al.
Publicado: (2014)

Expression and regulation of discoidin domain receptor 1 (DDR1) – a novel receptor for collagen – in normal human renal cells and patients with lupus nephritis
por: Boumpas, DT, et al.
Publicado: (2003)

Outcome prediction in ICU admitted end-stage renal disease patients
por: Mahnès, G, et al.
Publicado: (2001)

Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis
por: Koopman, Jacob J E, et al.
Publicado: (2020)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Poor methodological reporting in lupus clinical trials found in Cochrane reviews
por: Goldsmith, CH
Publicado: (2012)

Lupus Nephritis in Males: Clinical Features, Course, and Prognostic Factors for End-Stage Renal Disease
por: Urrestarazú, Andrés, et al.
Publicado: (2017)

In situ cognate interactions between T-follicular helper cells and B cells characterize severe tubulointerstitial inflammation in human lupus nephritis
por: Clark, MR, et al.
Publicado: (2012)

Comparison of quality-of-care measures in U.S. patients with end-stage renal disease secondary to lupus nephritis vs. other causes
por: Plantinga, Laura C, et al.
Publicado: (2015)

Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease
por: Gómez-Puerta, José A, et al.
Publicado: (2013)

Metastatic pulmonary calcification on bone scintigraphy of a patient with lupus nephritis and end-stage renal disease
por: Cheng, Nina H., et al.
Publicado: (2023)

Dialysis and Pregnancy in End Stage Kidney Disease Associated with Lupus Nephritis
por: Sivasuthan, Goutham, et al.
Publicado: (2013)

Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
por: Mahajan, Anadi, et al.
Publicado: (2020)

Comparison of Clinical Outcomes by Different Renal Replacement Therapy in Patients with End-Stage Renal Disease Secondary to Lupus Nephritis
por: Kang, Seok-Hui, et al.
Publicado: (2011)

Renal Fibrosis in Lupus Nephritis
por: Sciascia, Savino, et al.
Publicado: (2022)

Listeria peritonitis in a patient on hemodialysis for end‐stage renal disease secondary to lupus nephritis—a case report
por: Cox, Victor Frederick, et al.
Publicado: (2023)

Targeted delivery of PGE(2 )ameliorates autoimmune nephritis
por: Kvirkvelia, Nino, et al.
Publicado: (2014)

Biopsy-verified response of severe lupus nephritis to rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to NIH-protocol cyclophosphamide
por: van Vollenhoven, RF, et al.
Publicado: (2002)

Renal microvascular lesions in lupus nephritis
por: Ding, Ying, et al.
Publicado: (2019)

Renal Mononuclear Phagocytes in Lupus Nephritis
por: Davidson, Anne
Publicado: (2021)

Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy
por: Nieto-Ríos, John Fredy, et al.
Publicado: (2016)

Cytokine imbalance in NZB/W mice is associated with autoantibody levels and nephritis
por: Enghard, P, et al.
Publicado: (2004)

Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

The spectrum of renal thrombotic microangiopathy in lupus nephritis
por: Song, Di, et al.
Publicado: (2013)

Prediction of prognosis and renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2020)

Lupus Nephritis Associated With Renal Cell Carcinoma
por: Mehta, Vivek, et al.
Publicado: (2022)

Epigenetics and lupus
por: Richardson, B
Publicado: (2012)

Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?
por: Panagiotopoulos, Alexandros, et al.
Publicado: (2023)

Lymphoma risk in systemic lupus: effects of treatment versus disease activity
por: Clarke, AE, et al.
Publicado: (2012)

Vasculitis and Systemic Lupus Erythematous (SLE)
por: Cortis, Elisabetta, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_563vd3qubs72td57f6nec93tmn